BAJAJ BROKING
Morepen Laboratories Ltd. reported its Q4 FY24-25 financial results with a 29.3% decline in consolidated net profit to Rs.20.31 crore compared to Rs.28.74 crore in the same quarter last year. While revenue rose 10.1% YoY to Rs.465.85 crore, weaker margins and reduced EBITDA weighed on overall profitability.
Revenue: Rs.465.85 crore, up 10.1% YoY from Rs.423.74 crore
Net Profit: Rs.20.31 crore, down 29.3% YoY from Rs.28.74 crore
EBITDA: Rs.42.6 crore, down 12.6% YoY from Rs.48.4 crore
EBITDA Margin: 9% in Q4 FY25 vs. 11.4% in Q4 FY24
Morepen Labs posted mixed results in Q4 FY25, with revenue growing moderately but profitability metrics showing weakness. The company’s margin contraction from 11.4% to 9% suggests rising input costs or pricing pressures. EBITDA also fell 12.6% YoY to Rs.42.6 crore, while net profit dipped by 29.3% YoY.
While a detailed segmental breakdown was not disclosed, the core pharma and diagnostics business likely faced margin pressure due to supply-side cost escalations. Growth in top-line revenue indicates sustained demand across key business lines, but operational efficiency has lagged behind expectations.
The pharma sector was expected to post moderate revenue growth with stable margins in Q4 FY25. Compared to peers, Morepen Labs delivered decent revenue gains but underperformed on profitability metrics. The margin drop is a key deviation from broader sector trends which largely maintained EBITDA levels.
Management has yet to release an official statement, but the earnings report highlights the need for margin stabilisation. Cost rationalisation and supply chain management may be key focus areas going forward, especially to improve EBITDA and net profit performance in the coming quarters.
Metric | Q4 FY24-25 | Q4 FY23-24 | YoY Change (%) |
Revenue from Operations | Rs.465.85 crore | Rs.423.74 crore | +10.1% |
EBITDA | Rs.42.60 crore | Rs.48.40 crore | -12.6% |
EBITDA Margin (%) | 9.0% | 11.4% | -240 bps |
Net Profit (PAT) | Rs.20.31 crore | Rs.28.74 crore | -29.3% |
PAT Margin (%) | 4.36% | 6.78% | -242 bps |
Volume Traded (BSE/NSE) | 59.15 lakh | – | – |
Share Price (End of Day) | Rs.60.36 | – | +7.10% (Intraday) |
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Source: Morepen Lab – Board Meeting Outcome and Audited Q4 FY25 Financial Results
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading